Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 52 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
PHARMACIE GILMARD from Namur, company number BE0478958185, closed financial year 2025 with a result of € 34,359 after tax. For that financial year PHARMACIE GILMARD recorded a gross margin of € 279,535 and equity of € 130,479. Compared with financial year 2024, the result moved from € 101,090 to € 34,359. The company is profitable. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 28, 2026.
€ 130,479
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 34,359
▼ 66% vs 2024
Profit after tax over the fiscal year.
€ 226,435
▼ 28% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 34,000 paid out
99 % of the profit went to the shareholders, mostly to PHARMA & FLO (100 % of the shares). That is where the money ends up.
People and assets in 2025
3.5
▼ 0.7 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 203,169
▼ 9% vs 2024
€ 58,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
€ 187,755
▼ 12% vs 2024
€ 27,226 is repaid this year. At this pace the long-term loan is gone in ≈ 7 years.
€ 110,232
▲ 65% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 21,802
▼ 33% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 374,043 | € 412,705 | € 387,829 | € 279,535 | ▼ 28% |
| Profit after taxes | € 108,830 | € 121,769 | € 101,090 | € 34,359 | ▼ 66% |
| Equity | € 127,261 | € 129,030 | € 130,120 | € 130,479 | |
| Total debts | € 817,326 | € 889,441 | € 946,820 | € 857,198 | ▼ 9% |
| Cash | € 216,247 | € 201,557 | € 313,528 | € 226,435 | ▼ 28% |
| Land & buildings | € 492,000 | € 474,000 | € 456,000 | € 438,000 | ▼ 4% |
| Retained profit | € 107,261 | € 109,030 | € 110,120 | € 110,479 | |
| Dividend | € 100,000 | € 120,000 | € 100,000 | € 34,000 | ▼ 66% |
| Bank debt | € 266,797 | € 240,882 | € 214,537 | € 187,755 | ▼ 12% |
| Balance sheet total | € 944,587 | € 1,018,472 | € 1,076,940 | € 987,677 | ▼ 8% |
| Employees (FTE) | 3.8 | 3.7 | 4.2 | 3.5 | ▼ 0.7 |
Key figures of PHARMACIE GILMARD, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PHARMACIE GILMARD?
What happened at PHARMACIE GILMARD in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 34,359 (▼ 66% vs 2024). filed late Source: NBB ↗
- New establishment in Namur. KBO
- Start of the company according to the CBE. KBO
In short
From € 108,830 profit in 2022 to € 34,359 profit in 2025.
Paid € 125,845 in corporate taxes since 2022.
Best year ever: 2023, with € 121,769 profit.
On average € 79,900 of value added per employee in 2025.
A new publication or filing at PHARMACIE GILMARD? We notify you, reason included.
Follow PHARMACIE GILMARDDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of PHARMA & FLO comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
PHARMACIE GILMARDBehind PHARMACIE GILMARD is PHARMA & FLO. The shares are held by PHARMA & FLO (100%).
Directors
According to the 2025 annual accounts
Director · represented by THIERRY DELAHAUT
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Avenue de Marlagne 2
5000 Namur
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0478.958.185
- VAT number
- BE 0478.958.185
- Registered office
- Avenue de Marlagne 2, 5000 Namur
- Names & denominations
- PHARMACIE GILMARD
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 6 December 2002
- Peppol
- Active · Active since 9 Jan 2026
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers
Detailhandel in cosmetica en toiletartikelen
Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen
Detailhandel in medische en orthopedische artikelen
Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels